Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302
News Nov 03, 2008
Evotec AG announced encouraging results of a Phase I safety study investigating the potential interaction of EVT 302, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B) in development for smoking cessation, with tyramine.
The study was undertaken to determine potential safety advantages of EVT 302 versus non-selective MAO inhibitors and less selective MAO-B inhibitors already on the market. These MAO inhibitors are known to interact with tyramine, a natural constituent of some drinks or food such as red wine, cheese or chocolate.
In extreme cases, the interaction can dangerously elevate blood pressure. As a result, some agents require patients to adhere to strict dietary restrictions to prevent the intake of food containing high levels of tyramine.
The study results showed that at the lowest dose tested, predicted to be at least twice the therapeutic dose, EVT 302, like placebo, did not increase the sensitivity to tyramine. Doses of EVT 302 for the current study were chosen based on the previously performed human PET imaging studies which showed that the lowest dose chosen for this study was already supramaximal for full inhibition of brain MAO-B.
Selegiline was included as a control as it is a marketed MAO-B inhibitor with less subtype selectivity than EVT 302. At its recommended therapeutic dose selegiline does not require dietary restrictions, although it increases tyramine sensitivity slightly. Higher doses produce more dramatic increases in tyramine sensitivity. In this study, the therapeutic dose of selegiline did increase the sensitivity to tyramine compared to placebo.
At the highest EVT 302 dose tested, a small increase in tyramine sensitivity was produced, which was within the range of that produced by the therapeutic dose of selegiline.
Tyramine when ingested with food is normally metabolized by MAO-A, and it is inhibition of this form of MAO by older generation MAO inhibitors which results in the potential for tyramine interaction. Such interaction with tyramine was not expected with EVT 302 since it is highly selective for MAO-B. Preclinical and clinical studies have demonstrated EVT 302 can achieve complete blockade of MAO-B without inhibition of MAO-A.
The study was performed double blind in 59 healthy young male subjects. The study assessed whether EVT 302 resulted in an increase in the sensitivity to tyramine in enhancing blood pressure. The study included selegiline, a marketed MAO-B inhibitor with less selectivity than EVT 302 over MAO-A, and as an active comparator.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE